Demographics
A total of 36 healthy male subjects were enrolled in the study. Age, height, weight and BMI were 33.0 ± 6.0 years (mean ± standard deviation), 173.7 ± 5.3 cm, 68.8 ± 7.7 kg and 22.8 ± 2.0 kg/m2, respectively. The baseline demographic characteristics were similar across sequence groups. During the study, one subject discontinued before drug administration due to non-treatment emergent adverse event, and one subject withdrew consent in the first period of the study. Therefore, 35 subjects who received study drug at least once were included in safety assessment, and 34 subjects who completed the whole study were included in pharmacokinetic and pharmacodynamic assessment.